Clinical Characteristics, Treatment Approaches, and Survival Predictors in Adult Acute Myeloid Leukemia: Interim Results from the Turkish Society of Hematology AML Registry
Year: 2025
Type: article
Study design: Observational Study
Abstract: Background: Acute myeloid leukemia (AML) is an aggressive and biologically diverse hematologic cancer that disproportionately affects older individuals. Despite advances in molecular profiling and therapy, long-term outcomes remain unsatisfactory. This nationwide registry was established to provide real-world insights into clinical characteristics, treatment strategies, and survival among adult AML patients in Turkey. Methods: The Turkish AML Registry Project (ClinicalTrials.gov Identifier: NCT05979675) combines retrospective and prospective data from 23 tertiary hematology centers. Adult patients diagnosed between January 2008 and July 2023 were included. Baseline demographics, European LeukemiaNet (ELN) 2017 risk groups, Eastern Cooperative Oncology Group (ECOG) performance status, treatment intensity, and targeted therapy use were analyzed. Response and survival outcomes were assessed using Kaplan–Meier methods. Results: The interim dataset included 891 patients (median age 58 years, 45.5% ≥60). Intensive chemotherapy, most commonly 7 + 3, was applied in 74.1%, while 25.9% received lower-intensity regimens. Targeted agents, mainly venetoclax, were incorporated more frequently into low-intensity therapies (19.1% vs. 3.4%, p < 0.001). Complete remission occurred in 70.2% after intensive and 35.9% after low-intensity therapy, improving to 51.4% with targeted agents. Median overall survival (OS) was 27.2 months, with 1-year OS rates of 54.1%, 28.9%, and 17.6% for favorable, intermediate, and adverse ELN groups (p < 0.001). ECOG 0–1 predicted superior survival (1-year OS 70.3% vs. 47.0%). Conclusions: Nationwide real-world evidence underscores the prognostic relevance of ELN risk and functional status in AML. While intensive chemotherapy remains central, combining targeted agents with low-intensity regimens improves outcomes in less fit patients and supports personalized treatment approaches.
Source: Journal of Clinical Medicine
DOI: 10.3390/jcm14207367
Authors: Volkan Karakus, Ibrahim Ethem Pinar, Utku Iltar, Emel Merve Yenihayat, Merve Gokcen Polat, Serhat Celik, Umit Yavuz Malkan, Guldane Cengiz Seval, Ali Dogan, Aydan Akdeniz, Demircan Ozbalci, Idris Ince, Ramazan Erdem, Ozgur Mehtap, Hakki Onur Kirkizlar, Murat Kacmaz, Burak Deveci, Fatma Aykas, Gulten Korkmaz, Sureyya Yigit Kaya, Hacer Berna Afacan Ozturk, Omur Gokmen Sevindik, Ferda Can, Demet Cekdemir, Ceyda Aslan, Hale Bulbul, Zeynep Tugba Karabulut, Senem Maral, Salih Sertac Durusoy, Fatih Demirkan, Hakan Goker, Fahir Ozkalemkas, Muzaffer Keklik, Selami Kocak Toprak, Aylin Fatma Karatas, Unal Atas, Inci Alacacioglu
Institutions: Antalya Eğitim ve Araştırma Hastanesi, Sağlık Bilimleri Üniversitesi, Bursa Uludağ Üni̇versi̇tesi̇, Akdeniz University, Kocaeli Üniversitesi, Erciyes University, Hacettepe University, Ankara University, Van Yüzüncü Yıl Üniversitesi, Mersin Üniversitesi, Süleyman Demirel Üniversitesi, Trakya University, Mustafa Kemal University, Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi, Istanbul Medipol University, Izmir Tepecik Eğitim ve Araştırma Hastanesi, Health Sciences University Derince Training and Research Hospital, Niğde Ömer Halisdemir Üniversitesi, Sanko University, Dokuz Eylül University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,137
OpenAlex ID: W4415357676